Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Drugs  Nov 16, 2021  2 years, 5 months, 2 days, 11 hours, 49 minutes ago

University of California And Stanford Study Shows SSRI Antidepressants Like Fluoxetine Or Fluvoxamine Lowers Risk Of COVID-19 Mortality

University of California And Stanford Study Shows SSRI Antidepressants Like Fluoxetine Or Fluvoxamine Lowers Risk Of COVID-19 Mortality
Source: COVID-19 Drugs  Nov 16, 2021  2 years, 5 months, 2 days, 11 hours, 49 minutes ago
COVID-19 Drugs: University of California-San Francisco and Stanford University researchers have in a new study involving the meta-analysis of health records from 87 health care centers across America found that individuals taking a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), especially Fluoxetine or Fluvoxamine were significantly less likely to die of COVID-19 than a matched control group.

Antidepressant use may be associated with reduced levels of several proinflammatory cytokines suggested to be involved with the development of severe COVID-19. An association between the use of selective serotonin reuptake inhibitors (SSRIs) specifically fluoxetine hydrochloride and fluvoxamine maleate with decreased mortality among patients with COVID-19 has been reported in recent studies; however, these studies had limited power due to their small size. https://www.thailandmedical.news/news/the-together-randomized-clinical-trials-shows-that-fluvoxamine-reduces-risk-of-covid-19-disease-severity-and-reduces-need-for-hospitalization
 
https://www.thailandmedical.news/news/breaking-randomized-clinical-trial-findings-confirms-that-early-treatment-with-fluvoxamine-reduces-risk-of-covid-19-severity-and-mortality
 
https://www.thailandmedical.news/news/breaking-fluvoxamine-an-inexpensive-anti-depressant-emerging-as-a-leading-drug-candidate-to-be-repurposed-to-treat-covid-19
 
In this multicenter cohort study analyzing electronic health records of 83 584 patients diagnosed with COVID-19, including 3401 patients who were prescribed SSRIs, a reduced relative risk of mortality was found to be associated with the use of SSRIs specifically fluoxetine compared with patients who were not prescribed SSRIs.
 
A total of 3401 adult patients with COVID-19 prescribed SSRIs (2033 women [59.8%]; mean [SD] age, 63.8 [18.1] years) were identified, with 470 receiving fluoxetine only (280 women [59.6%]; mean [SD] age, 58.5 [18.1] years), 481 receiving fluoxetine or fluvoxamine (285 women [59.3%]; mean [SD] age, 58.7 [18.0] years), and 2898 receiving other SSRIs (1733 women [59.8%]; mean [SD] age, 64.7 [18.0] years) within a